A Phase 2 interventional study of 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) and 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) in Acne Vulgaris, sponsored by Biofrontera Inc.. Completed at 9 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Biofrontera Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 158th largest by enrollment of the 354 interventional ones that give a count, is one of 15 that started in 2021, is one of 65 in phase 2, and was the 308th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 15 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 354 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
287 of 374 have an industry lead sponsor. The 10 most frequent:
Biofrontera Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Biofrontera Inc. has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
10 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 374 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with sunburn or other possible confounding skin conditions (e.g. wounds, irritations, bleeding or skin infections) within or in close proximity (\< 5 cm distance) to treatment field. (Reassessment of subjects is allowed once if the sunburn or other confounding skin conditions is/are expected to resolve within the screening period.
Reassessment can be done on the day of the actual treatment.)
(CS) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject's safety such as:
Any topical medication of the skin prior to screening as defined below:
Any use of the below specified systemic treatments within the designated periods:
Dosing Day exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
Combination Product: 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
Combination Product: 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps). Other Names: ALA-PDT, Ameluz®-PDT
The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps). Other Names: ALA-PDT, Ameluz®-PDT
The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
Relative Change in the Number of Inflammatory Lesions (Relative Change From Baseline) 8 Weeks After the Last PDT as Assessed by Investigator.
Outcome 1 is the relative change in the number of inflammatory lesions at the final visit with respect to baseline as assessed by the investigator.
Time frame: 8 weeks after the last PDT
Treatment Success Defined by a Minimum Improvement of the Modified Investigator Global Assessment (mIGA) Score by at Least 2 Assessed 8 Weeks After the Last PDT and Resulting in an mIGA Score of 0 (Clear) or 1 (Almost Clear).
Treatment success is defined as a minimum improvement of the mIGA score by at least 2 and resulting in an mIGA score of 0 (clear) or 1 (almost clear).
Time frame: 8 weeks after the last PDT
Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT
Time frame: 4 or 8 weeks after the last PDT
Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT
Time frame: 4 or 8 weeks after the last PDT
Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3
Time frame: 4 or 8 weeks after the last PDT
Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3
Time frame: 4 or 8 weeks after the last PDT
Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1
Time frame: 4 or 8 weeks after PDT-1
Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1
Time frame: 4 or 8 weeks after PDT-1
Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2
Time frame: 4 or 8 weeks after PDT-2
Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2
Time frame: 4 or 8 weeks after PDT-2
Absolute Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.
In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3
Time frame: 4 or 8 weeks after PDT-3
Percentage Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.
In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3
Time frame: 4 or 8 weeks after PDT-3
Absolute Change in the Number of Nodules & Cysts
The number of nodules and cysts was assessed by investigator.
Time frame: 8 weeks after the last PDT
Percentage Change in the Number of Nodules & Cysts
The number of nodules and cysts was assessed by investigator. Percentage change from baseline was calculated only for participants whose number of nodules and cysts had changed at 8 weeks after the last PDT.
Time frame: 8 weeks after the last PDT
Treatment Success Defined by a Minimum Improvement of the IGA by at Least 2.
Treatment success is defined as a minimum improvement of the IGA score by at least 2 (from baseline (Visit 2) as assessed by investigator).
Time frame: 8 weeks after the last PDT
Improvement of the IGA.
As assessed by the investigator.
Time frame: 8 weeks after the last PDT
Improvement of the mIGA.
As assessed by the investigator.
Time frame: 8 weeks after the last PDT
Improvement of Scar Severity and Overall Esthetic Appearance.
Improvement of scar severity: As assessed by the investigator via a physical global scale for acne scars (PGA). Overall esthetic appearance: As assessed by the investigator using a 4-point scale (0= very good, 1 = good, 2 = satisfactory, 3 = unsatisfactory)
Time frame: 8 weeks after last PDT
Satisfaction Regarding Esthetic Outcome and Treatment.
As reported by the subject. Subject's Satisfaction with PDT (No = No, I would not choose this treatment again; Yes = Yes, I would choose this treatment again) Assessment of Esthetic Outcome (0=Very good, 1=Good, 2=Satisfactory, 3=Unsatisfactory)
Time frame: 8 weeks after the last PDT.
Frequency and Severity of Adverse Events (AEs), Serious AEs (SAEs), AEs of Special Interest (AESI) and Treatment-emerged Adverse Events (TEAEs).
TEAEs are defined as all AEs with onset on or after first treatment with randomized IMP up to study termination of the subject.
Time frame: from screening to study completion, over a duration of up to approximately 25 weeks
Application Site Skin Reaction Assessed by Investigator
Only local skin reactions with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.
Time frame: During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
Application Site Discomfort Reported by the Subjects.
Only local skin discomforts with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.
Time frame: During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
Pain During Illumination Reported by the Subject.
Subject's pain intensity during illumination is assessed at the end of illumination period using a numeric rating pain scale ranging from no pain at all (0) to worst possible pain (10). The maximum of pain score over across both illumination areas for PDT-1, PDT-2 and PDT-3 is shown.
Time frame: During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
Changes in Blood Pressure
Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\]. Findings which differed from reference range and were considered clinically significant were to be reported.
Time frame: at all clinic visits conducted over a duration of approximately 25 weeks
Changes in Heart Rate
Number of patients with changes in heart rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.
Time frame: at all clinic visits conducted over a duration of approximately 25 weeks
Investigation of Clinical Chemistry Parameters
Findings which differ from reference range and are considered to be clinically significant are to be reported.
Time frame: first and last visit conducted up to approximately 25 weeks apart
Investigation of Hematology Parameters
Number of patients with changes in hematology parameters. Findings which differed from reference range and were considered clinically significant were to be reported.
Time frame: first and last visit conducted up to approximately 25 weeks apart
Investigation of Urinalysis Parameters
Number of patients with changes in urinalysis parameters. Findings which differed from reference range and were considered clinically significant were to be reported.
Time frame: first and last visit conducted up to approximately 25 weeks apart
Physical Examination of Head, Neck, Skin, Lymph Nodes, Thorax Including Heart and Lungs, Abdomen, and Musculoskeletal, Peripheral Vascular and Nervous System Status
Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.
Time frame: first and last visit conducted up to approximately 25 weeks apart
| Milestone | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | 1h Incubation Vehicle | 3h Incubation Vehicle |
|---|---|---|---|---|
| Started | 42 | 36 | 21 | 21 |
| Completed | 29 | 21 | 15 | 14 |
| Not completed | 13 | 15 | 6 | 7 |
| Withdrew: Adverse event | 2 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 2 | 3 | 0 |
| Withdrew: Sponsor request | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 6 | 1 | 4 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Forbidden medication | 2 | 4 | 1 | 0 |
| Withdrew: Subject decision | 0 | 0 | 0 | 1 |
| Withdrew: Joint decision of subject and investigator | 1 | 0 | 0 | 0 |
Outcome 1 is the relative change in the number of inflammatory lesions at the final visit with respect to baseline as assessed by the investigator.
| percentage change from baseline | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Relative Change in the Number of Inflammatory Lesions (Relative Change From Baseline) 8 Weeks After the Last PDT as Assessed by Investigator. | -37.89 ± 39.92 | -48.69 ± 31.75 | -38.84 ± 41.84 |
Treatment success is defined as a minimum improvement of the mIGA score by at least 2 and resulting in an mIGA score of 0 (clear) or 1 (almost clear).
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Treatment Success Defined by a Minimum Improvement of the Modified Investigator Global Assessment (mIGA) Score by at Least 2 Assessed 8 Weeks After the Last PDT and Resulting in an mIGA Score of 0 (Clear) or 1 (Almost Clear). | 5 | 7 | 8 |
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT
| lesions | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| a. Inflammatory lesions - 4 weeks after the last PDT | -9.0 ± 12.8 | -18.9 ± 13.4 | -15.2 ± 21.7 |
| b. Inflammatory lesions - 8 weeks after the last PDT | -7.3 ± 11.6 | -19.6 ± 14.3 | -15.4 ± 23.1 |
| c. Non-inflammatory lesions - 4 weeks after the last PDT | -5.6 ± 24.7 | -18.2 ± 29.6 | -16.3 ± 27.0 |
| d. Non-inflammatory lesions - 8 weeks after the last PDT | -8.6 ± 15.4 | -22.8 ± 27.8 | -16.7 ± 28.6 |
| e. Infl. & non-inflammatory lesions - 4 weeks after the last PDT | -14.6 ± 32.1 | -37.1 ± 33.5 | -31.5 ± 45.0 |
| f. Infl. & non-inflammatory lesions - 8 weeks after the last PDT | -16.0 ± 22.0 | -42.4 ± 31.9 | -32.0 ± 48.1 |
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT
| percentage | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| a. Inflammatory lesions - 4 weeks after the last PDT | -37.92 ± 45.09 | -55.24 ± 28.04 | -44.05 ± 41.12 |
| b. Inflammatory lesions - 8 weeks after the last PDT | -31.99 ± 43.16 | -58.98 ± 26.74 | -43.68 ± 40.61 |
| c. Non-inflammatory lesions - 4 weeks after the last PDT | -18.70 ± 61.88 | -36.60 ± 40.00 | -42.27 ± 39.71 |
| d. Non-inflammatory lesions - 8 weeks after the last PDT | -28.35 ± 38.80 | -46.36 ± 41.97 | -42.23 ± 40.13 |
| e. Infl. & non-inflammatory lesions - 4 weeks after the last PDT | -28.13 ± 46.20 | -45.82 ± 30.57 | -43.63 ± 36.25 |
| f. Infl. & non-inflammatory lesions - 8 weeks after the last PDT | -29.68 ± 36.25 | -54.04 ± 29.45 | -42.09 ± 36.31 |
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3
| lesions | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| a. Inflammatory lesions - 4 weeks after PDT-1 | -6.8 ± 7.6 | -9.4 ± 10.9 | -9.4 ± 14.5 |
| b. Non-inflammatory lesions - 4 weeks after PDT-1 | -4.1 ± 15.8 | -15.0 ± 18.3 | -11.8 ± 14.7 |
| c. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 | -10.9 ± 17.4 | -24.4 ± 23.0 | -21.2 ± 27.2 |
| d. Inflammatory lesions - 4 weeks after PDT-2 | -9.3 ± 13.9 | -17.2 ± 14.4 | -15.2 ± 19.7 |
| e. Non-inflammatory lesions - 4 weeks after PDT-2 | -5.4 ± 17.4 | -20.0 ± 28.9 | -17.7 ± 24.7 |
| f. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 | -14.7 ± 21.8 | -37.2 ± 32.3 | -32.8 ± 41.3 |
| g. Inflammatory lesions - 4 weeks after PDT-3 | -8.8 ± 13.0 | -19.8 ± 12.9 | -16.6 ± 21.5 |
| h. Non-inflammatory lesions - 4 weeks after PDT-3 | -3.7 ± 22.6 | -19.2 ± 29.9 | -18.3 ± 26.8 |
| i. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 | -12.5 ± 30.3 | -39.0 ± 32.9 | -34.8 ± 44.4 |
| j. Inflammatory lesions - 8 weeks after PDT-3 | -7.3 ± 11.6 | -19.6 ± 14.3 | -15.4 ± 23.1 |
| k. Non-inflammatory lesions - 8 weeks after PDT-3 | -8.6 ± 15.4 | -22.8 ± 27.8 | -16.7 ± 28.6 |
| l. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3 | -16.0 ± 22.0 | -42.4 ± 31.9 | -32.0 ± 48.1 |
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3
| percentage | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| a. Inflammatory lesions - 4 weeks after PDT-1 | -26.02 ± 27.26 | -34.72 ± 33.34 | -30.65 ± 34.55 |
| b. Non-inflammatory lesions - 4 weeks after PDT-1 | -11.40 ± 45.48 | -31.89 ± 29.92 | -33.13 ± 34.53 |
| c. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 | -20.01 ± 27.18 | -32.28 ± 27.14 | -31.71 ± 29.18 |
| d. Inflammatory lesions - 4 weeks after PDT-2 | -36.49 ± 49.95 | -50.87 ± 25.76 | -44.66 ± 32.24 |
| e. Non-inflammatory lesions - 4 weeks after PDT-2 | -16.83 ± 45.60 | -39.34 ± 37.22 | -47.18 ± 30.81 |
| f. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 | -27.21 ± 33.57 | -45.25 ± 25.73 | -45.04 ± 25.75 |
| g. Inflammatory lesions - 4 weeks after PDT-3 | -37.36 ± 45.72 | -58.14 ± 24.90 | -48.58 ± 35.99 |
| h. Non-inflammatory lesions - 4 weeks after PDT-3 | -16.73 ± 61.86 | -39.09 ± 39.08 | -48.09 ± 33.52 |
| i. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 | -26.66 ± 46.19 | -48.51 ± 28.36 | -48.68 ± 30.50 |
| j. Inflammatory lesions - 8 weeks after PDT-3 | -31.99 ± 43.16 | -58.98 ± 26.74 | -43.68 ± 40.61 |
| k. Non-inflammatory lesions - 8 weeks after PDT-3 | -28.35 ± 38.80 | -46.36 ± 41.97 | -42.23 ± 40.13 |
| l. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3 | -29.68 ± 36.25 | -54.04 ± 29.45 | -42.09 ± 36.31 |
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1
No measurements were reported for this outcome.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1
No measurements were reported for this outcome.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2
No measurements were reported for this outcome.
In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2
No measurements were reported for this outcome.
In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3
| lesions | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| a. Inflammatory lesions - 4 weeks after PDT-3 | — | -21 ± 0 | — |
| b. Inflammatory lesions - 8 weeks after PDT-3 | — | -21 ± 0 | — |
| c. Non-Inflammatory lesions - 4 weeks after PDT-3 | — | 1 ± 0 | — |
| d. Non-Inflammatory lesions - 8 weeks after PDT-3 | — | -22 ± 0 | — |
| e. Inflammatory & non-inflammatory lesions - 4 weeks after PDT-3 | — | -20 ± 0 | — |
| f. Inflammatory & non-inflammatory lesions - 8 weeks after PDT-3 | — | -43 ± 0 | — |
In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3
| percentage | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| a. Inflammatory lesions - 4 weeks after PDT-3 | — | -100 ± 0 | — |
| b. Inflammatory lesions - 8 weeks after PDT-3 | — | -100 ± 0 | — |
| c. Non-Inflammatory lesions - 4 weeks after PDT-3 | — | 4.17 ± 0 | — |
| d. Non-Inflammatory lesions - 8 weeks after PDT-3 | — | -91.67 ± 0 | — |
| e. Inflammatory & non-inflammatory lesions - 4 weeks after PDT-3 | — | -44.44 ± 0 | — |
| f. Inflammatory & non-inflammatory lesions - 8 weeks after PDT-3 | — | -95.56 ± 0 | — |
The number of nodules and cysts was assessed by investigator.
| lesions | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Nodules | -0.2 ± 1.3 | -0.1 ± 1.1 | -0.2 ± 1.0 |
| Cysts | 0 ± 1.0 | 0 ± 0.4 | -0.2 ± 0.6 |
TEAEs are defined as all AEs with onset on or after first treatment with randomized IMP up to study termination of the subject.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| AEs | 40 | 35 | 31 |
| SAEs | 0 | 1 | 1 |
| AESIs | 0 | 0 | 0 |
| TEAEs | 40 | 35 | 31 |
| Any TEAE related to IMP and/or IMD | 40 | 35 | 27 |
| Any TEAE related to IMP and/or IMD, mild | 38 | 33 | 26 |
| Any TEAE related to IMP and/or IMD, moderate | 24 | 24 | 10 |
| Any TEAE related to IMP and/or IMD, severe | 6 | 11 | 2 |
Only local skin reactions with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Application Site Skin Reaction Assessed by Investigator | 4 | 8 | 2 |
Only local skin discomforts with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Application Site Discomfort Reported by the Subjects. | 38 | 31 | 21 |
Subject's pain intensity during illumination is assessed at the end of illumination period using a numeric rating pain scale ranging from no pain at all (0) to worst possible pain (10). The maximum of pain score over across both illumination areas for PDT-1, PDT-2 and PDT-3 is shown.
| pain score | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| PDT-1 | 2.3 ± 2.3 | 3.4 ± 3.0 | 0.7 ± 1.4 |
| PDT-2 | 2.5 ± 2.2 | 3.8 ± 3.2 | 0.5 ± 0.9 |
| PDT-3 | 2.0 ± 2.2 | 3.7 ± 2.9 | 0.6 ± 1.7 |
Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\]. Findings which differed from reference range and were considered clinically significant were to be reported.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Screening | 0 | 0 | 0 |
| Baseline/PDT-1 | 0 | 0 | 0 |
| 4 weeks post PDT-1/PDT-2 | 0 | 0 | 0 |
| 4 weeks post PDT-2/PDT-3 | 0 | 0 | 0 |
| 4 weeks post PDT-3 | 0 | 0 | 0 |
| 8 weeks post PDT-3 | 0 | 0 | 0 |
Number of patients with changes in heart rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Screening | 0 | 0 | 0 |
| Baseline/PDT-1 | 0 | 0 | 0 |
| 4 weeks post PDT-1/PDT-2 | 0 | 0 | 0 |
| 4 weeks post PDT-2/PDT-3 | 0 | 0 | 0 |
| 4 weeks post PDT-3 | 0 | 0 | 0 |
| 8 weeks post PDT-3 | 0 | 0 | 0 |
Findings which differ from reference range and are considered to be clinically significant are to be reported.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Screening — No clinically significant clinical chemistry parameters reported | 40 | 32 | 35 |
| Screening — Clinically significant clinical chemistry parameters reported | 1 | 0 | 1 |
| 8 weeks post PDT-3 — No clinically significant clinical chemistry parameters reported | 26 | 19 | 26 |
| 8 weeks post PDT-3 — Clinically significant clinical chemistry parameters reported | 1 | 0 | 0 |
Number of patients with changes in hematology parameters. Findings which differed from reference range and were considered clinically significant were to be reported.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Screening | 0 | 0 | 0 |
| 8 weeks post PDT-3 | 0 | 0 | 0 |
Number of patients with changes in urinalysis parameters. Findings which differed from reference range and were considered clinically significant were to be reported.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Screening | 0 | 0 | 0 |
| 8 weeks post PDT-3 | 0 | 0 | 0 |
Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Screening — No clinically significant physical examination findings reported | 40 | 35 | 41 |
| Screening — Clinically significant physical examination findings reported | 2 | 0 | 1 |
| 8 weeks post PDT-3 — No clinically significant physical examination findings reported | 29 | 21 | 29 |
| 8 weeks post PDT-3 — Clinically significant physical examination findings reported | 0 | 0 | 0 |
The number of nodules and cysts was assessed by investigator. Percentage change from baseline was calculated only for participants whose number of nodules and cysts had changed at 8 weeks after the last PDT.
| percentage | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Nodules | -69.39 ± 74.88 | -16.67 ± 98.32 | -80.95 ± 37.80 |
| Cysts | -6.25 ± 141.97 | -100.00 ± 0 | -100.00 ± 0 |
Treatment success is defined as a minimum improvement of the IGA score by at least 2 (from baseline (Visit 2) as assessed by investigator).
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Treatment Success Defined by a Minimum Improvement of the IGA by at Least 2. | 5 | 6 | 7 |
As assessed by the investigator.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Improvement of the IGA. | 15 | 13 | 20 |
As assessed by the investigator.
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Improvement of the mIGA. | 24 | 21 | 25 |
Improvement of scar severity: As assessed by the investigator via a physical global scale for acne scars (PGA). Overall esthetic appearance: As assessed by the investigator using a 4-point scale (0= very good, 1 = good, 2 = satisfactory, 3 = unsatisfactory)
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Acne Scarring Improved | 6 | 4 | 10 |
| Esthetic Appearance, 0=Very good | 1 | 3 | 5 |
| Esthetic Appearance, 1=Good | 10 | 9 | 10 |
| Esthetic Appearance, 2=Satisfactory | 13 | 7 | 12 |
| Esthetic Appearance, 3=Unsatisfactory | 4 | 2 | 2 |
As reported by the subject. Subject's Satisfaction with PDT (No = No, I would not choose this treatment again; Yes = Yes, I would choose this treatment again) Assessment of Esthetic Outcome (0=Very good, 1=Good, 2=Satisfactory, 3=Unsatisfactory)
| Participants | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Subject's Satisfaction with PDT, No | 8 | 3 | 2 |
| Subject's Satisfaction with PDT, Yes | 21 | 18 | 26 |
| Assessment of Esthetic Outcome, 0=Very good | 7 | 8 | 10 |
| Assessment of Esthetic Outcome, 1=Good | 12 | 7 | 11 |
| Assessment of Esthetic Outcome, 2=Satisfactory | 5 | 3 | 4 |
| Assessment of Esthetic Outcome, 3=Unsatisfactory | 5 | 3 | 3 |
Collected over Collection of AEs starts with signing the informed consent documents until the final visit (up to 27 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1h Incubation BF-200 ALA | 0/42 (0%) | 0/42 (0%) | 40/42 (95.2%) |
| 3h Incubation BF-200 ALA | 0/36 (0%) | 1/36 (2.8%) | 35/36 (97.2%) |
| Vehicle (1h and 3h Incubation Pooled) | 0/42 (0%) | 1/42 (2.4%) | 31/42 (73.8%) |
| Event | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/42 | 1/36 | 0/42 |
| ManiaPsychiatric disorders | 0/42 | 0/36 | 1/42 |
| Event | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | Vehicle (1h and 3h Incubation Pooled) |
|---|---|---|---|
| Application site painGeneral disorders | 35/42 | 34/36 | 17/42 |
| Application site pruritusGeneral disorders | 35/42 | 30/36 | 13/42 |
| Application site erythemaGeneral disorders | 15/42 | 14/36 | 11/42 |
| Application site exfoliationGeneral disorders | 8/42 | 8/36 | 4/42 |
| Application site oedemaGeneral disorders | 3/42 | 8/36 | 3/42 |
| Application site drynessGeneral disorders | 7/42 | 3/36 | 2/42 |
| Application site paraesthesiaGeneral disorders | 6/42 | 2/36 | 3/42 |
| Application site warmthGeneral disorders | 5/42 | 1/36 | 4/42 |
| AcneSkin and subcutaneous tissue disorders | 2/42 | 3/36 | 5/42 |
| Application site discolourationGeneral disorders | 0/42 | 3/36 | 1/42 |
| Age, Customized(Participants) | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | 1h Incubation Vehicle | 3h Incubation Vehicle | Total |
|---|---|---|---|---|---|
| 16-17 | 7 | 13 | 2 | 7 | 29 |
| >=18 years | 35 | 23 | 19 | 14 | 91 |
| Sex: Female, Male(Participants) | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | 1h Incubation Vehicle | 3h Incubation Vehicle | Total |
|---|---|---|---|---|---|
| Female | 24 | 22 | 14 | 13 | 73 |
| Male | 18 | 14 | 7 | 8 | 47 |
| Race (NIH/OMB)(Participants) | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | 1h Incubation Vehicle | 3h Incubation Vehicle | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 3 | 4 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 6 | 2 | 4 | 19 |
| White | 31 | 25 | 14 | 14 | 84 |
| More than one race | 2 | 0 | 0 | 1 | 3 |
| Unknown or Not Reported | 0 | 2 | 1 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | 1h Incubation Vehicle | 3h Incubation Vehicle | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 4 | 1 | 18 |
| Not Hispanic or Latino | 35 | 29 | 17 | 20 | 101 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Fitzpatrick Skin Type Category(Participants) | 1h Incubation BF-200 ALA | 3h Incubation BF-200 ALA | 1h Incubation Vehicle | 3h Incubation Vehicle | Total |
|---|---|---|---|---|---|
| Type I - III | 24 | 21 | 9 | 14 | 68 |
| IV-VI | 18 | 15 | 12 | 7 | 52 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2021 to primary completion in Aug 2025, 44 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 44 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biofrontera Inc.